Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Malta to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis.
Customer preferences: Maltese customers prefer inhalers over other forms of bronchodilator drugs such as tablets or syrups. This is due to the convenience and ease of use of inhalers, which allow for quick relief of symptoms. Additionally, customers tend to prefer branded drugs over generic ones, as they perceive them to be of higher quality.
Trends in the market: The Bronchodilator Drugs market in Malta has been steadily growing over the past few years. This can be attributed to the increasing prevalence of respiratory diseases in the country, as well as the growing awareness and diagnosis of these conditions. The market has also seen a shift towards more advanced and innovative inhaler technologies, such as dry powder inhalers and smart inhalers, which offer improved efficacy and ease of use.
Local special circumstances: Malta has a high prevalence of respiratory diseases, with asthma being one of the most common chronic conditions in the country. This is due to a combination of factors, including air pollution, smoking, and genetic predisposition. Additionally, Malta has a high elderly population, who are more susceptible to respiratory diseases and require more frequent use of bronchodilator drugs.
Underlying macroeconomic factors: The healthcare sector in Malta is highly regulated, with the government playing a significant role in the provision and funding of healthcare services. The country has a publicly-funded healthcare system, which provides free or heavily subsidized healthcare to all citizens and residents. This has led to a high demand for bronchodilator drugs, as they are widely prescribed and subsidized by the government. However, the government’s budget constraints and increasing healthcare costs may impact the availability and affordability of these drugs in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
